{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-26-000058","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2026-07-22T11:10:49+00:00","discovered_at":"2026-07-22T11:15:00.306496+00:00","generated_at":"2026-07-22T11:15:04.976439+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Summit reports updated OS HR 0.76 for ivonescimab in HARMONi; consistent in western and Asian patients","bullets":["Updated OS analysis from Phase III HARMONi shows HR 0.76 for full ITT population and western subgroup.","Western patients median follow-up now 23.2 months; Asian patients locked at 32.7 months.","Ivonescimab plus chemo continues to show acceptable safety profile; no new safety signals.","BLA for ivonescimab in EGFR-mutated NSCLC under FDA review; PDUFA date November 14, 2026.","Results made available to FDA; detailed data planned for presentation at upcoming medical conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-26-000058","json":"https://secwatch.observer/filing/0001599298-26-000058.json","markdown":"https://secwatch.observer/filing/0001599298-26-000058.md","text":"https://secwatch.observer/filing/0001599298-26-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000058/0001599298-26-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000058/smmt-20260722.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-22T11:15:04.976439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}